Resulting from performance concerns of many devices, questions have surfaced on whether the current postmarket surveillance system is “optimally structured to meet the challenges of rapidly evolving medical devices and the changing nature of health care delivery and information technology.” This was noted in a recent release in the Federal Register which also announced the public meeting being held by FDA to examine the issue of postmarket surveillance.